SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?


To: LLCF who wrote (6554)3/19/1999 1:44:00 PM
From: Volsi Mimir  Respond to of 9719
 
Genzyme Transgenics Corporation and Millennium BioTherapeutics Collaborate to Develop Transgenic Therapeutic Proteins and Antibodies

[both in the portfolio][nice pop for GZTC, then, think that will continue?....]
eddy.

FRAMINGHAM, Mass. and CAMBRIDGE, Mass., March 17 /PRNewswire/ -- Genzyme Transgenics Corporation (Nasdaq: GZTC - news) and Millennium BioTherapeutics, Inc. (MBio), a majority-owned subsidiary of Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - news) today announced that they have signed a collaborative agreement to initiate two projects utilizing MBio's expertise in therapeutic drug discovery and Genzyme Transgenics Corporation's capabilities in the development of transgenically produced biotherapeutics.